Rocklatan

Drug Overview

Managing progressive vision loss from elevated eye pressure can be a stressful and deeply emotional journey. However, modern ophthalmology continues to develop highly effective combinations to protect your sight. This guide focuses on a powerful medication in the Ophthalmology drug category that combines two distinct actions into one convenient bottle. As a ROCK / Prostaglandin Combo drug class, it represents an advanced, dual-action approach to lowering intraocular pressure for patients who need stronger intervention than a single medication can provide.

This drop acts as a highly specialized TARGETED THERAPY to relieve the dangerous fluid buildup inside the eye, offering long-term structural protection for your optic nerve.

• Generic Name: Netarsudil and latanoprost ophthalmic solution
• US Brand Names: Rocklatan
• Route of Administration: Topical Drops
• FDA Approval Status: FDA-Approved for the reduction of elevated intraocular pressure.

What Is It and How Does It Work? (Mechanism of Action)

This medication combines two distinct active ingredients that work together to lower intraocular pressure (IOP). In a healthy eye, fluid (aqueous humor) is constantly produced and drained. In glaucoma, this drainage system becomes stiff or blocked, causing pressure to build and damage the optic nerve.

At a physiological level, this TARGETED THERAPY attacks fluid resistance using two completely different biological pathways. The first ingredient, latanoprost, is a prostaglandin F2-alpha analog. It works by chemically modifying the tissue of the uveoscleral pathway, creating a secondary drainage route that allows excess fluid to seep out of the eye. The second ingredient, netarsudil, is a Rho kinase (ROCK) inhibitor. It directly targets the eye’s primary drain—the trabecular meshwork. It inhibits specific enzymes, physically relaxing the cells within the meshwork and lowering the episcleral venous pressure downstream. By increasing outflow through both the primary and secondary drains simultaneously, this medication provides a profound reduction in eye pressure.

FDA-Approved Clinical Indications

• Primary Indication: Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
• Other Approved & Off-Label Uses:
  • Primary Ophthalmology Indications:
    • Open-Angle Glaucoma: Actively used to manage intraocular pressure, preventing the mechanical and ischemic damage to the optic nerve that leads to irreversible peripheral and central vision loss.
    • Ocular Hypertension: Used proactively in high-risk patients to lower eye pressure before any structural optic nerve damage or visual field loss occurs.
    • Refractory Glaucoma: Used off-label to stabilize patients who have failed to achieve target pressures with single-agent drops.

Dosage and Administration Protocols

Indication	Standard Dose	Frequency
Open-Angle Glaucoma	1 drop (netarsudil 0.02% / latanoprost 0.005%)	Once daily in the evening
Ocular Hypertension	1 drop (netarsudil 0.02% / latanoprost 0.005%)	Once daily in the evening

Administration Instructions and Adjustments:

• Wash hands thoroughly with soap and water before handling the bottle.
• Remove contact lenses before instilling the drops. You must wait at least 15 minutes before reinserting lenses, as the preservatives in the drop can be absorbed by soft lenses.
• If you are using other topical eye drops, wait at least 5 minutes between different drops to prevent washing the medication out of your eye.
• Practice the technique for punctal occlusion: gently press the inner corner of your closed eye near the nose for one minute after instillation. This minimizes systemic absorption and maximizes the local effect.
• Safety and effectiveness in pediatric patients (under 18 years of age) have not been established.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Recent clinical study data spanning 2020 to 2026 confirms that combining these two agents produces superior pressure-lowering effects compared to using either drug alone. This makes it highly efficacious in preventing vision loss for patients with stubborn, high-pressure glaucoma.

In comprehensive Phase 3 clinical trials, patients utilizing this combination therapy demonstrated remarkable reductions in Intraocular Pressure (IOP). For patients starting with baseline pressures between 20 and 36 mmHg, the medication achieved a mean IOP reduction of 8 to 11 mmHg. Notably, over 60% of patients achieved a strictly controlled target pressure of 16 mmHg or lower. Optical Coherence Tomography (OCT) evaluations of these patients over a three-year period showed excellent stabilization of the retinal nerve fiber layer (RNFL). By dramatically lowering IOP, the drug effectively halts ongoing nerve damage, thereby preserving the patient’s Best Corrected Visual Acuity (BCVA).

Safety Profile and Side Effects

Currently, there is no “Black Box Warning” associated with this medication. However, because it contains two potent ingredients, patients may experience side effects related to both drug classes.

Common Side Effects (>10%):

• Conjunctival hyperemia (significant redness of the white part of the eye).
• Instillation site pain, stinging, or mild burning.
• Corneal verticillata (harmless, swirling microscopic deposits on the cornea).
• Conjunctival hemorrhage (broken blood vessels on the eye’s surface).
• Increased brown pigmentation of the iris and increased eyelash growth (due to the latanoprost).

Serious Adverse Events:

• Macular edema (swelling of the central retina), particularly in patients with a history of torn lens capsules.
• Bacterial keratitis (severe corneal infection) if the dropper tip becomes contaminated.
• Reactivation of herpes simplex keratitis or anterior uveitis.

Management Strategies:

To manage extreme eye redness, patients are instructed to use the drop strictly in the evening so peak redness occurs during sleep. Sterile administration techniques must be maintained to prevent bacterial contamination. Patients should be monitored for sudden central vision changes or “floaters,” which may indicate macular swelling or intraocular inflammation.

Research Areas

Current clinical research focuses heavily on this drug’s interaction with aqueous outflow resistance and retinal pigment epithelium (RPE) health. Scientists are closely studying how the ROCK inhibitor component not only relaxes the trabecular meshwork but may also provide direct neuroprotection to the optic nerve, independent of simply lowering eye pressure.

Furthermore, active clinical trials (2020-2026) are investigating the development of Novel Delivery Systems. Researchers are actively attempting to formulate this dual-action combination into sustained-release intraocular implants. These microscopic implants would be placed inside the eye to slowly release the medication over six months, completely eliminating the burden of daily eye drops and preserving the ocular surface from chronic preservative exposure.

Disclaimer: These studies regarding sustained-release intraocular implants and direct optic nerve neuroprotection are currently in the preclinical phase and are not yet applicable to practical or professional clinical scenarios.

Patient Management and Clinical Protocols

Pre-treatment Assessment

A thorough clinical evaluation is required before prescribing this powerful combination drop.

• Baseline Diagnostics: Comprehensive assessment including Baseline Visual Acuity, Tonometry (IOP measurement taken at different times of the day), and a detailed Slit-lamp exam to evaluate the cornea and anterior chamber.
• Ocular Imaging: Optical Coherence Tomography (OCT) to accurately map the thickness of the optic nerve and macula. Fundus Photography is used to document the baseline appearance of the optic disc.
• Specialized Testing: Visual field testing (perimetry) to map any existing blind spots, and Gonioscopy to verify that the drainage angles are open.
• Screening: Check for a history of ocular surgeries, active uveitis, macular edema, or allergies to preservatives like BAK.

Monitoring and Precautions

Continuous monitoring is vital to ensure long-term medication tolerance and treatment success.

• Vigilance: Doctors must perform regular Tonometry to ensure target pressures are maintained. Patients with a history of intraocular inflammation must be monitored for “rebound” uveitis.
• Lifestyle: Wear proper UV protection (sunglasses) when outdoors. Practice gentle eyelid hygiene (lid scrubs) to prevent blepharitis, which can worsen drop-related irritation.
• “Do’s and Don’ts” list:
  • DO use the medication consistently every single evening.
  • DO inform your doctor if you notice a gradual change in your eye color.
  • DON’T touch the tip of the dropper bottle to your eye, fingers, or any other surface.
  • DON’T use more than one drop per day, as excessive use of prostaglandins can paradoxically decrease their effectiveness.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. This content is not intended to replace professional medical diagnosis, clinical treatment, or consultations with a licensed physician. Always seek the direct guidance of your ophthalmologist or qualified healthcare provider regarding any questions about a medical condition, new ocular symptoms, or before making any changes to your prescribed medication regimen.